Estimating economic cost of HIV/AIDS-related diseases

Irina Farquhar; Alan Sorkin; Kent Summers; Earl Weir

doi:10.1016/S0194-3960(01)14007-2

Login

Welcome:
Guest

Search for:

Browse:

Product Information:

Resources:

Research in Human Capital and Development

ISSN: 0194-3960
Series editor(s): Professor Irene Farquhar

Subject Area: Human Resource Management

Content: Series Volumes | Current Volume RSS

Options: To add Favourites and Table of Contents Alerts please take a Emerald profile

Document request:
Estimating economic cost of HIV/AIDS-related diseases

Document Information:
Title:	Estimating economic cost of HIV/AIDS-related diseases
Author(s):	Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir
Volume:	14 Editor(s): Irina Farquhar, Kent Summers, Alan Sorkin ISBN: 978-0-76230-697-8 eISBN: 978-1-84950-070-8
Citation:	Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir (2001), Estimating economic cost of HIV/AIDS-related diseases, in Irina Farquhar, Kent Summers, Alan Sorkin (ed.) Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development, Volume 14), Emerald Group Publishing Limited, pp.143-173
DOI:	10.1016/S0194-3960(01)14007-2 (Permanent URL)
Publisher:	Emerald Group Publishing Limited
Article type:	Full length article
Abstract:	The study considers annual health care utilization and costs associated with human immunodeficiency virus (HIV) infection and the autoimmune disease syndrome (AIDS) complex by applying the previously developed disease and disease combination-specific cost of illness methodology. This study documents changes in age-specific mortality rates indicating the decline in age groups “20–39”. We estimate annual economic losses resulting from twenty-four HIV/AIDS-related diseases among the U.S. population to be $18.2 billion. This estimate includes direct medical cost of almost $9.2 billion, 80% of which is compensated by Medicaid. We demonstrate that an add-on therapy with additional mean cost of $7,100 per person per year would be justifiable if it could reduce the risk of progression to AIDS by 19%.